Private Equity Isn’t The Real Issue In Healthcare. Competition Is

Why It Matters

The findings show that market competition, rather than private‑equity ownership, determines cost dynamics, guiding regulators to focus on preserving competitive landscapes.

Key Takeaways

• PE ownership doesn't raise negotiated dental reimbursement rates
• Revenue growth stems from higher list prices, service mix shift
• Medicaid participation remains stable under private‑equity control
• Competition, not ownership, determines pricing power
• Future consolidation could enable contract renegotiations and higher prices

Pulse Analysis

Private equity’s surge into health‑care has ignited a policy firestorm, with critics warning of price inflation and supporters touting capital‑driven efficiency. Dentistry, long characterized by fragmented ownership, offers a concrete lens to test these claims. A recent analysis conducted with the American Dental Association examined a cohort of practices acquired by private‑equity firms, tracking changes in insurer contracts, service pricing, and patient mix. The findings challenge the simplistic narrative that PE automatically translates into higher negotiated rates, suggesting that market dynamics, not ownership alone, shape outcomes. Moreover, the timing coincides with a higher‑interest‑rate environment that compresses acquisition valuations, forcing PE firms to prioritize operational efficiency over financial engineering.

Instead of raising contracted fees, PE‑backed clinics boosted their list prices and tilted treatment portfolios toward higher‑margin restorative procedures. Because insurers continued to reimburse at existing rates, revenue gains derived from a richer case mix rather than bargaining leverage. Importantly, the study observed no dip in Medicaid participation, dispelling fears that private capital would crowd out low‑income patients. These adjustments also create incentives for clinicians to recommend more complex procedures, raising questions about care quality and patient outcomes.

The broader lesson for regulators is clear: competition, not the label of ownership, is the decisive guard against price escalation. In markets where private‑equity roll‑ups eventually dominate, the balance of power can shift, enabling firms to renegotiate contracts from a position of scarcity. Policymakers should therefore focus on preserving network flexibility, encouraging new entrants, and scrutinizing mergers that raise local concentration metrics. A proactive antitrust review that incorporates future concentration scenarios can preempt the shift from operational tweaks to outright price power. By safeguarding competitive discipline, the health‑care system can reap the capital benefits of private investment without surrendering patients to unchecked cost growth.